Liquid Biopsy Market at a CAGR of 18.1% by 2026| Myriad Genetics, Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., Guardant Health, Inc., MDxHealth SA

Liquid Biopsy Market research report has been produced with the systematic gathering of market information for the Healthcare industry. All this information is supplied in such a way that it properly gives an explanation of various facts and figures to the business. The market data provided in this report helps to discover diverse market opportunities present worldwide for the Healthcare industry. This report gives accurate information about market trends, industrial changes, and consumer behaviour, etc. Taking up such a market research report is always very advantageous for any company, whether it is a small scale or large scale, for marketing of products or services. Analytical study of Liquid Biopsy Market report helps in mapping growth strategies to increase sales and build brand image in the market.

Request for FREE Sample Report: To Know the Impact of COVID-19 on this Industry at: https://www.reportsnreports.com/contacts/requestsample.aspx?name=631133

Lists of Companies Profiled in the Report:

F. Hoffmann-La Roche Ltd. (Switzerland)
Myriad Genetics, Inc. (US)
QIAGEN N.V. (Netherlands)
Thermo Fisher Scientific, Inc. (US)
Guardant Health, Inc. (US)
MDxHealth SA (Belgium)
Exact Sciences Corporation (US)
Illumina Inc. (US)
Sysmex Inostics (US)
Bio-Rad Laboratories, Inc. (US)
Biocept, Inc. (US)
NeoGenomics, Inc. (US)
ANGLE plc (UK)
Menarini-Silicon Biosystems (Italy)
Vortex Biosciences, Inc. (US)
Exosome Diagnostics, Inc. (US)
Agena Bioscience, Inc. (US)
MedGenome Inc. (US)
Epigenomics AG (Germany)
Personal Genome Diagnostics, Inc. (US)

The global liquid biopsy market is projected to reach USD 5.8 billion by 2026 from USD 2.5 billion in 2021, at a CAGR of 18.1% during the forecast period.

Market growth is driven by factors such as the rising incidence & prevalence of cancer and the increasing preference for noninvasive treatment procedures. On the other hand, the lower sensitivity of certain liquid biopsies might act as a restraining factor to the growth of this market.

“The assay kits segment accounted for the highest growth rate in the liquid biopsy market, by product& service, during the forecast period”

The liquid biopsy market is segmented into assay kits, instruments, and services based on product & service. In 2020, the assay kits segment accounted for the highest growth rate in the liquid biopsy market. The availability of a wide range of reagents and kits, easy accessibility to a wide range of assays, and the rising prevalence of cancer are the major factors driving the growth of the liquid biopsy assay kits market.

“Non-cancer applications segment accounted for the highest CAGR”

Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications. In 2020, the non-cancer application segment accounted for the highest growth rate. This can be attributed to the increasing research activities in NIPT and organ transplant diagnosis.

“Asia Pacific: The fastest-growing region liquid biopsy market”

The global liquid biopsy market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period.

The Asia Pacific region is projected to register the highest CAGR during the forecast period. Factors such as government efforts to increase awareness about the early detection of diseases and regular health check-ups, continuously rising healthcare expenditure, increasing number of hospitals, clinical diagnostic laboratories in India and China, and strengthening research base for diagnostic procedures across India, China, and Japan are expected to boost the market growth. Furthermore, supportive government regulations will further aid the growth of this market during the forecast period.

The primary interviews conducted for this report can be categorized as follows:

By Company Type: Tier 1 - 40%, Tier 2 - 30%,and Tier 3 -30%
By Designation: C-level - 27%, D-level - 18%, and Others - 55%
By Region: North America -51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa – 4%

Research Coverage:

This report provides a detailed picture of the global liquid biopsy market. It aims at estimating the size and future growth potential of the market across different segments, such as product& service, clinical application, technology, circulating biomarkers, application, and end-user. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall liquid biopsy market and its sub-segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

Purchase this report (FLAT 20% Discount. Coupon Code: DEC20) at: https://www.reportsnreports.com/purchase.aspx?name=631133

Contact Us:

Corporate Headquarters
Tower B5, office 101,
Magarpatta SEZ,
Hadapsar, Pune-411013, India
+ 1 888 391 5441
sales@reportsandreports.com

About Us:

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

This release was published on openPR.